10.19USD-6.60%Mkt Cap: 549.51M USDP/E: —Last update: 2026-05-26
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap549.51M USD
Enterprise Value346.84M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-324.25M USD
Revenue/Share—
Last Price10.19 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees384
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.91
PEG—
EV/EBITDA-1.12
EV/Revenue—
P/S—
P/B1.10
EPS (TTM)-6.32
EPS (Forward)-5.84
52W Range
7.90024% of range17.40
52W High17.40 USD
52W Low7.900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE36.89%
ROA-54.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-188.52M USD
CapEx (TTM)46.74M USD
FCF Margin—
FCF Yield—
Net Debt-257.35M USD
Net Debt/EBITDA0.83
Balance Sheet
Debt/Equity-0.29
Current Ratio11.75
Quick Ratio11.37
Book Value/Sh10.17 USD
Cash/Share9.461 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)25.20 USD
Target Range5.000 USD – 34.00 USD
# Analysts5
Ownership
Shares Out.54.14M
Float27.52M
Insiders18.58%
Institutions64.20%
Short Interest
Short Ratio11.9d
Short % Float8.31%
Short % Out.6.26%
Shares Short3.39M
Short (prev mo.)3.31M
Technical
SMA 5010.64 (-4.3%)
SMA 20011.93 (-14.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)292.09K
Avg Vol (10d)453.97K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—